	US 12,257,234 B2
	Methods of treating fibrotic liver diseases or conditions with indeglitazar
Prasad Manchem, Carlsbad, CA (US); and Joseph L. Evans, Saint Louis, MO (US)
Assigned to PLEIOGENIX INC., Carlsbad, CA (US)
Filed by PLEIOGENIX INC., Carlsbad, CA (US)
Filed on Jul. 12, 2024, as Appl. No. 18/771,595.
Claims priority of provisional application 63/532,001, filed on Aug. 10, 2023.
Claims priority of provisional application 63/526,840, filed on Jul. 14, 2023.
Prior Publication US 2025/0017901 A1, Jan. 16, 2025
Int. Cl. A61K 31/404 (2006.01); A61K 31/522 (2006.01); A61K 31/53 (2006.01); A61K 31/573 (2006.01); A61P 1/16 (2006.01)

CPC A61K 31/404 (2013.01) [A61K 31/522 (2013.01); A61K 31/53 (2013.01); A61K 31/573 (2013.01); A61P 1/16 (2018.01)]

22 Claims

1. A method of treating alcoholic hepatitis in a subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.